Search results
Beacon Therapeutics raises $170M in series B to advance gene therapies for eye disease
BioPharma-Reporter· 15 hours agoBeacon Therapeutics has closed a $170 million series B round led by Forbion, and joined by Syncona,...
The Zacks Analyst Blog Highlights Eli Lilly, Sanofi Merck, AstraZeneca's and Roche
Zacks via Yahoo Finance Canada· 2 days agoThis will lower treatment costs and burden for patients. Kisunla will be the second drug on the...
FDA approves Kisunla for early Alzheimer's treatment amid cognitive decline slowdown
BioPharma-Reporter· 6 days agoDonanemab, which will be known as Kisunla, has been given full approval by the US Food and Drug...
U.S. Regulator Approves Eli Lilly’s Alzheimer’s Drug
Baystreet· 7 days agoThe U.S. Food and Drug Administration (FDA) has approved pharmaceutical company Eli Lilly’s (LLY) Alzheimer’s drug called “Donanemab.” Eli Lilly’s medication for early-stage Alzheimer’s disease ...
FDA approves new Alzheimer’s drug that slows memory decline - National | Globalnews.ca
Global B.C.· 7 days agoThe U.S. Food and Drug Administration on Tuesday approved Eli Lilly’s treatment for early Alzheimer’s, making it the second therapy for slowing progression of the brain-wasting disease that ...
Factbox-Lilly follows Biogen-Eisai in securing US FDA approval for Alzheimer's drug
Reuters via Yahoo Canada News· 7 days agoKisunla is now the second drug to get a traditional approval from the U.S. regulator for the...
